Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lexaria Bioscience Corp - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
LEXX
Nasdaq
2833
https://www.lexariabioscience.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lexaria Bioscience Corp
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space
- May 26th, 2022 12:30 pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
- May 25th, 2022 12:30 pm
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
- Apr 21st, 2022 2:39 pm
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
- Apr 21st, 2022 1:05 pm
LEXX: Hypertension Results Raise Stakes
- Apr 19th, 2022 3:38 pm
Lexaria Commences Multi-Week Human Clinical Hypertension Study
- Apr 19th, 2022 1:05 pm
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
- Apr 14th, 2022 12:45 pm
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
- Apr 12th, 2022 1:10 pm
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
- Apr 11th, 2022 1:00 pm
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
- Mar 15th, 2022 6:05 pm
Lexaria Granted Important New Oral Nicotine Patent
- Mar 8th, 2022 2:15 pm
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
- Feb 2nd, 2022 2:25 pm
LEXX: 1Q:22 Results & Other Things that Came Up
- Feb 2nd, 2022 11:38 am
Lexaria Provides Annual Letter From the CEO
- Jan 27th, 2022 2:35 pm
IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka
- Jan 20th, 2022 1:00 pm
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
- Jan 18th, 2022 2:25 pm
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
- Dec 29th, 2021 4:15 pm
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
- Dec 16th, 2021 7:45 pm
LEXX: An R&D Extravaganza
- Dec 16th, 2021 4:33 pm
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
- Dec 14th, 2021 4:50 pm
Scroll